{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ROSETTA CRC-203","nct_id":"NCT07221357","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rosetta-crc-203-nct07221357. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm A1","type":"EXPERIMENTAL"},{"description":null,"label":"Arm A2","type":"EXPERIMENTAL"},{"description":null,"label":"Arm B","type":"OTHER"},{"description":null,"label":"Arm C","type":"EXPERIMENTAL"},{"description":null,"label":"Arm D","type":"OTHER"}],"collaborators":["BioNTech SE"],"completion_date":{"date":"2034-03-11","type":"ESTIMATED"},"conditions":["Untreated, Unresectable, or Metastatic Colorectal Cancer"],"enrollment":{"count":990,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pumitamig","otherNames":["BMS-986545","BNT327","PM8002"],"type":"DRUG"},{"name":"FOLFOX","otherNames":[],"type":"DRUG"},{"name":"FOLFIRI","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"CAPOX","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Bristol-Myers Squibb","official_title":"ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2030-02-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response (OR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment","timeFrame":"Up to 5 years"},{"measure":"Progression Free Survival (PFS) by RECIST v1.1 per blinded independent central review (BICR)","timeFrame":"Up to 5 years"},{"measure":"Overall Survival (OS)","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2025-12-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT07221357"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rosetta-crc-203-nct07221357"}